NEW YORK (GenomeWeb) – An international team of researchers has used a CRISPR activation (CRISPRa) screen to identify both coding and noncoding pathways involved in acquired resistance to cytarabine, the main treatment for acute myeloid leukemia (AML).

The study, led by senior author Pier Paolo Pandolfi of the Beth Israel Deaconess Medical Center and Harvard Medical School, was published in Cell today.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York Times and ProPublica say that many physicians fail to disclose their financial ties when publishing in medical journals.

The Wall Street Journal reports Human Longevity's valuation has dropped by 80 percent.

Science reports that the US National Cancer Institute is cutting its operating budget by 5 percent.

In PLOS this week: similar variants seen in bullbogs, people with Robinow syndrome; ApoE genotypes in African-American, Puerto Rican populations; and more.